Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences

Rhea-AI Summary

Mustang Bio, Inc. (NASDAQ: MBIO), a clinical-stage biopharmaceutical company, announced participation in three virtual investor conferences in January 2022. The events include the 11th Annual LifeSci Partners Corporate Access Event (Jan 5-7), H.C. Wainwright Virtual BioConnect Conference (presentation available Jan 10), and B. Riley Securities’ Virtual Oncology Conference (fireside chat on Jan 28). Webcasts of the presentations will be accessible on Mustang's website for approximately 30 days post-event. Mustang aims to develop cell and gene therapies for various cancers and rare diseases.

WORCESTER, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2022.

Details of the events are as follows:

• 11^th Annual LifeSci Partners Corporate Access Event: The company will host virtual one-on-one meetings during the conference on Wednesday, January 5 through Friday, January 7, 2022.
• H.C. Wainwright Virtual BioConnect Conference: The company’s presentation will be available for on-demand viewing on Mustang’s website beginning Monday, January 10, 2022, at 7:00 a.m. EST.
• B. Riley Securities’ Virtual Oncology Conference: The company’s fireside chat will take place on Friday, January 28, 2022, at 12:30 p.m. EST and will be available to all conference-registered institutional investors.
  

Webcasts of the H.C. Wainwright presentation and B. Riley fireside chat will be available on the Events page of the Investors Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days following each meeting.

About Mustang Bio
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, to fund research and development, and to outlicense or bring the technologies to market. Mustang has partnered with top medical institutions to advance the development of CAR-T therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Mustang is registered under the Securities Exchange Act of 1934, as amended, and files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). Mustang was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.mustangbio.com.

Forward‐Looking Statements
This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks relating to our growth strategy; our ability to obtain, perform under, and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contacts:
Jaclyn Jaffe and Bill Begien
Mustang Bio, Inc.
(781) 652-4500
ir@mustangbio.com

Investor Relations Contact:
Daniel Ferry
LifeSci Advisors, LLC
(617) 430-7576
daniel@lifesciadvisors.com

Media Relations Contact:
Tony Plohoros
6 Degrees
(908) 591-2839
tplohoros@6degreespr.com

FAQ

What investor conferences is Mustang Bio participating in January 2022?

Mustang Bio will participate in the 11th Annual LifeSci Partners Corporate Access Event, H.C. Wainwright Virtual BioConnect Conference, and B. Riley Securities’ Virtual Oncology Conference.

When will Mustang Bio's presentation be available for viewing?

The presentation will be available on-demand starting January 10, 2022.

What is the date and time for the B. Riley Securities Oncology Conference fireside chat?

The fireside chat will take place on January 28, 2022, at 12:30 p.m. EST.

Where can I find the webcasts of Mustang Bio's presentations?

Webcasts will be available on Mustang's website for approximately 30 days after each event.

What is the focus of Mustang Bio's research?

Mustang Bio focuses on developing cell and gene therapies for hematologic cancers, solid tumors, and rare genetic diseases.